A higher internalization in HER-2-positive breast cancer cells (SKBR-3) was also appreciated in trastuzumab-grafted dendrimers containing neratinib, a tyrosine kinase inhibitor, as an anticancer drug. This evidence concerns the gene ERBB2 and breast carcinoma.